Compared with placebo, fostamatinib did not increase the number of oxygen-free days among adults hospitalized with COVID-19 and hypoxemia.

A study suggests that catching COVID-19 significantly raises the risk of developing ME/CFS (formerly called "chronic fatigue ...

New research emphasizes the need for ongoing COVID-19 protection for people with weakened immune systems, with scalable tests ...

Introduction During the first wave of the COVID-19 outbreak in China, the surge of COVID-19 cases was rapid and drastic. Emerging evidence suggests that beyond the acute phase, patients with COVID-19 ...

Paxlovid use was associated with lower rates of hospitalization and death, particularly among older adults, a new study finds ...

Women are at a higher risk of developing long Covid than men although men are more likely to suffer from severe Covid-19 ...

Faster post-COVID-19 recovery is observed after infection with the Omicron vs earlier variants, regardless of vaccination status.

Findings reveal fluoxetine's weak antiviral effects in COVID-19, with no significant benefits in symptom resolution compared to other antiviral treatments.

In this study, the authors estimated that Paxlovid reduced the risk of hospitalization by 39% (95% confidence interval [CI], ...

A research team from Queen’s University Belfast has mapped the introduction and spread of the SARS-CoV-2 virus across Ireland ...

One in 20 persons infected with Covid-19 has been affected by extreme fatigue, formally called chronic fatigue syndrome (CFS) ...